亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Real-world (rw) treatment (tx) patterns and clinical outcomes among patients (pts) with metastatic urothelial carcinoma (mUC) receiving first-line (1L) systemic tx and avelumab 1L maintenance (1LM): Results from the IMPACT UC-III study.

作者
Helen Moon,Chiemeka Ike,Valerie Morris,Ruth Wangia Dixon,Ivy Tonnu-Mihara,Christopher L. Crowe,Malvika Venkataraman,Mairead Kearney,John Barron
出处
期刊:JCO oncology practice [Lippincott Williams & Wilkins]
卷期号:20 (10_suppl): 390-390
标识
DOI:10.1200/op.2024.20.10_suppl.390
摘要

390 Background: Avelumab 1LM is a standard of care for pts with mUC that has not progressed after 1L platinum-based chemotherapy (PBC). Immuno-oncology (IO) monotherapy is considered in pts with mUC who are ineligible to receive PBC. Recently approved 1L tx options include enfortumab vedotin + pembrolizumab and nivolumab + gemcitabine/cisplatin. This US retrospective study examined pt characteristics, tx patterns, and clinical outcomes among pts with mUC receiving 1L tx, including avelumab 1LM. Methods: Pts with mUC (bladder cancer; stage IIIB or IV, or ≥2 claims with ICD-10 diagnoses for metastatic cancer) aged ≥18 years, who initiated 1L tx (index date) from Jan 1, 2020 to Jul 31, 2023, were identified from the Healthcare Integrated Research Database (HIRD®; claims and clinical data from the health plan’s Cancer Care Quality Program). Clinical outcomes, including time to next tx (TTNT; time from 1L tx initiation to second-line tx) and overall survival (OS), were evaluated post index date. Pt characteristics and tx patterns were summarized using descriptive statistics. Avelumab 1LM use was identified on/after June 30, 2020 and ≤90 d after 1L PBC discontinuation. OS from the start of 1L tx or 1LM was analyzed using Kaplan-Meier methodology. Results: Of 2,820 pts with mUC, 1L tx was PBC in 37.0% (n=1,044), IO monotherapy in 39.0% (n=1,099), and other tx in 24.0% (n=677; antibody-drug conjugates and non-PBC). Among pts who received 1L PBC, 15.0% (n=157) initiated avelumab 1LM within 90 days of completing 1L PBC. Avelumab uptake in 2020-2023 by year was 10.8% (Jun-Dec 2020), 29.9%, 34.4%, and 24.8% (Jan-Aug 2023), respectively; 38.9% of pts were still receiving avelumab at the end of the study period. In the 1L PBC and IO cohorts, mean age (SD) was 65.5 (11.1) and 74.6 (10.7) years, respectively. 60% of pts were male. In the 1L PBC and 1L IO monotherapy cohorts, respectively, median follow-up (IQR) was 11.2 (5.6-20.3) and 8.6 (4.0-17.7) months (mo); median TTNT (IQR) was 4.8 (2.8-8.3) and 5.5 (2.8-11.0) mo; and median OS (95% CI) was 29.7 (25.1-37.2) and 20.0 (17.1-25.6) mo. In pts who received avelumab 1LM, median follow-up (IQR) from start of 1L PBC was 14.6 (9.2-21.3) mo; median TTNT (IQR) was 7.6 (6.2-12.3) mo; median time on avelumab tx was 5.0 (1.8-10.2) mo; and 1- and 2-year OS rates, respectively, from start of avelumab 1LM were 78% and 65%, and from start of 1L PBC were 84% and 68% (median OS was not estimable because >50% of pts remained alive at the end of the study period). Conclusions: Despite advances in 1L tx for mUC, IO monotherapy remains a prevailing option for older, commercially insured patients in the US. In this descriptive rw study, pts treated with 1L PBC had longer OS than pts treated with 1L IO monotherapy. Future studies with longer follow-up are needed to further evaluate pt outcomes.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Vicky完成签到,获得积分10
3秒前
神勇的天问完成签到 ,获得积分10
3秒前
萧雨墨发布了新的文献求助10
6秒前
6秒前
8秒前
10秒前
Sarah发布了新的文献求助10
16秒前
笑点低的丹蝶完成签到,获得积分10
17秒前
21秒前
完美世界的应助被Sarah采纳,获得10
24秒前
南尧z完成签到 ,获得积分10
26秒前
华仔的应助被晚风采纳,获得10
29秒前
霸气的似狮完成签到,获得积分10
30秒前
3D完成签到,获得积分10
36秒前
陨石拿铁完成签到,获得积分10
37秒前
xx完成签到 ,获得积分10
39秒前
水长聿完成签到,获得积分10
40秒前
40秒前
avoidant完成签到,获得积分10
45秒前
Maestro_S的应助被尊敬的芷卉采纳,获得10
46秒前
47秒前
fuz发布了新的文献求助10
49秒前
yl完成签到 ,获得积分10
51秒前
晚风发布了新的文献求助10
51秒前
如梦如画完成签到,获得积分10
1分钟前
明理冰海完成签到,获得积分10
1分钟前
fuz完成签到,获得积分20
1分钟前
科研通AI6.4的应助被dart1023采纳,获得10
1分钟前
imcwj完成签到 ,获得积分10
1分钟前
1分钟前
情怀的应助被晚风采纳,获得10
1分钟前
月亮完成签到 ,获得积分10
1分钟前
科研通AI6.4的应助被萧雨墨采纳,获得10
1分钟前
朱雀发布了新的文献求助10
1分钟前
1分钟前
辛勤的涵菡完成签到,获得积分10
1分钟前
萧雨墨发布了新的文献求助10
1分钟前
1分钟前
呼呼发布了新的文献求助10
1分钟前
Orange的应助被科研通管家采纳,获得10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190078
求助须知:如何正确求助?哪些是违规求助? 9577216
关于积分的说明 21851985
捐赠科研通 7788239
什么是DOI,文献DOI怎么找? 3436236
关于科研通互助平台的介绍 2559951
邀请新用户注册赠送积分活动 2482818